Meta AnalysisID 7635
胆碱酯酶抑制剂、美金刚与甘露特钠治疗阿尔茨海默病的疗效与安全性：贝叶斯网状Meta分析
CRD42023412516
Which drug has better efficacy and safety among the drugs currently used in clinical treatment of mild to moderate Alzheimer's disease?
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7635
- Evidence Id
- 16193
- Core Evidence Id
- 16193
- Source Meta Analysis Id
- 7629
- Herb2 Meta Analysis Id
- HBMA007629
- Crd Id
- CRD42023412516
- Title
- Efficacy and Safety of Cholinesterase Inhibitors, Memantine, and Sodium Oligomannate for the Treatment of Alzheimer’s Disease: a Bayesian network meta-analysis
- Review Question
- Which drug has better efficacy and safety among the drugs currently used in clinical treatment of mild to moderate Alzheimer's disease?
- Study Type Included
- • Inclusion: (1). there are direct and indirect comparisons between donepezil, galantamine, rivastigmine, memantine and sodium oligomannate; (2). patients with a possible diagnosis of AD following the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) or DSM-III-R or the National Institute of Neurological and Communicative Disorders and Stroke/AD and Related Disorders Association (NINCDS-ADRDA); (3). participants had mild-to-moderate AD, with a MMSE score from 10 to 27; (4). the course of treatment was at least 12 weeks, with measuring cognition, function, behavior, or global assessment once at least. • Exclusion: (1). patients with other neurodegenerative disease, encephalosis, or vascular dementia; (2). patients having severe AD (defined as the Mini-Mental State Examination (MMSE) < 10) or MCI; (3). we excluded studies that suffered from fatal flaws in design or analysis and trials whose data could not be readily accessed.
- Condition Being Studied
- Alzheimer’s disease(AD) is the most common cause of dementia, affecting more than 36 million people worldwide. It has been predicted that by 2050, this figure will more than 115 million.This age-associated neurodegenerative disorder has an insidious onset with progressive deterioration in cognition, functional ability, behavior, and mood. Regarding patients with mild-to-moderate AD, the American Psychiatric Association recommends second generation ChEIs, donepezil, galantamine and rivastigmine for mild-to-moderate AD. Memantine and sodium oligomannate were gradually added to the treatment in recent years, but controversy over these drugs still be continued.
- Participant
- • Inclusion: (1). there are direct and indirect comparisons between donepezil, galantamine, rivastigmine, memantine and sodium oligomannate; (2). patients with a possible diagnosis of AD following the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) or DSM-III-R or the National Institute of Neurological and Communicative Disorders and Stroke/AD and Related Disorders Association (NINCDS-ADRDA); (3). participants had mild-to-moderate AD, with a MMSE score from 10 to 27; (4). the course of treatment was at least 12 weeks, with measuring cognition, function, behavior, or global assessment once at least. Exclusion: (1). patients with other neurodegenerative disease, encephalosis, or vascular dementia; (2). patients having severe AD (defined as the Mini-Mental State Examination (MMSE) < 10) or MCI; (3). we excluded studies that suffered from fatal flaws in design or analysis and trials whose data could not be readily accessed.
- Animal
- Human Disease Modelled
- Intervention
- Donepezil, Galantamine, Rivastigmine, Memantine and sodium oligomannate
- Comparator Control
- Placebo or positive control
- Main Outcome
- We focus on the Alzheimer’s Disease Assessment Scale (ADAS-cog), Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS/ADL), Neuropsychiatric Inventory (NPI), and the Clinician’s Interview Based Assessment of Change-Plus (CIBIC plus) as the primary measure of cognition, function, behavior, and global assessment of change, respectively.
- Outcome Measure
- Additional Outcome
- we recorded the incidence of adverse events (AEs) as the second outcome to assess the safety of the different drug doses.
- Study Method
- Systematic review
- Keyword
- Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Cholinesterases; Humans; Memantine; Sodium
- Contact
- yan chen [email protected]
- Organisational Affiliation
- Zhejiang Chinese Medical University
- Funding Source
- Research and development of key technologies and core equipment for early screening and diagnosis of AD, Ministry of Science and Technology of the People's Republic of China（2022YFE0199300）
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-03-29
- Registration Date
- 2023-04-09
- Anticipated Start Date
- 2022-12-01
- Anticipated Completion Date
- 2023-04-30
- Title Cn
- 胆碱酯酶抑制剂、美金刚与甘露特钠治疗阿尔茨海默病的疗效与安全性：贝叶斯网状Meta分析
- Title En
- Efficacy and Safety of Cholinesterase Inhibitors, Memantine, and Sodium Oligomannate for the Treatment of Alzheimer’s Disease: a Bayesian network meta-analysis
- Bilingual Status
- complete